[Testicular cancer].
BACKGROUND
Testicular cancer is the most common type of cancer among Norwegian 15 to 40-year-old men. The incidence has doubled in Norway and Denmark during the last 50 years and is currently the highest in the world.


METHODS
The review article is based on relevant publications, own research and clinical experience.


CONCLUSIONS
Post-orchiectomy treatment is only offered at university hospitals. Cisplatin-based chemotherapy (introduced in Norway in the early 1980s) has resulted in a remarkably improved survival for patients with advanced testicular cancer. Most patients are cured (> 80%), also those with metastases. Cancer-related survival approaches 95%. Treatment-induced side effects and efforts to reduce these have been an issue of increasing importance during recent years.
Oldenburg
Jan
J
Fagområde Klinisk kreftforskning, Kreftklinikken Radiumhospitalet, Rikshospitalet, 0310 Oslo. jan.oldenburg@medisin.uio.no
Lehne
Gustav
G
Fosså
Sophie D
SD
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003718:Denmark / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D009664:Norway / Q000453:epidemiology; D009919:Orchiectomy; D018239:Seminoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality / Q000601:surgery
D000970:Antineoplastic Agents; D002945:Cisplatin